Exelixis (EXEL) The Citizens Life Sciences Conference 2026 summary

Financial performance and guidance

• Achieved $2.123 billion in revenue, with guidance targeting approximately $2.4 billion for 2026.

• Growth is driven by the RCC franchise and the recent launch in neuroendocrine tumors (NETs).

• Continued operational momentum is expected in both core RCC and newly launched NET indications.

Market opportunities and product strategy

• NET oral segment estimated at $1 billion, with a focus on maximizing penetration following recent approval.

• Strategic aim to become market leader in RCC, NETs, and CRC, leveraging multiple compounds across these franchises.

• Zanzalintinib (Zanza) program expanded to seven pivotal studies, targeting a $5 billion+ opportunity across GU and GI oncology.

• STELLAR-303 targets a $1.5 billion third-line-plus CRC market, with strong enthusiasm for the zanza/atezo combination.

Competitive landscape and clinical data

• LITESPARK-011 data seen as not practice-changing; combination therapies must show survival advantage over sequencing.

• RCC market dynamics may favor increased use of cabo/nivo in the front line as competitors shift to other combinations in later lines.

• Zanza positioned as a next-generation TKI, aiming to be the standard for the 2030s, with focus on optimized combinations and patient benefit.